Results of the univariable and multivariable analysis (adjusted on sex, age at disease onset, and disease duration) comparing anti-RNAP3− and anti-RNAP3+ patients at the last visit (n = 4939). Values are no./no. available data (%) unless otherwise specified.
| Characteristics | Univariable Analysis | Multivariable Analysis | ||||
|---|---|---|---|---|---|---|
| Anti-RNAP3− | Anti-RNAP3+ | p | Available Data, n (%) | OR (95% CI) | p* | |
| Age at disease onset, yrs, mean (SD), (n available) | 46.5 (14.2) (3946) | 46.4 (13.1) (140) | 0.981 | 4086 (82.7) | 0.461 | |
| Disease duration, mos, mean (SD), (n available) | 138.6 (102.6) (3943) | 131.0 (125.0) (140) | 0.391 | 4083 (82.7) | 0.843 | |
| Male | 684/4763 (14.4) | 45/176 (25.6) | < 0.0001 | 4939 (100.0) | 0.306 | |
| Ethnicity | ||||||
| White | 3425/3605 (95.0) | 134/144 (93.1) | 0.295 | 3749 (75.9) | ||
| Asian | 34/3605 (0.9) | 3/144 (2.1) | 0.175 | 3749 (75.9) | ||
| Black | 47/3605 (1.3) | 1/144 (0.7) | 0.524 | 3749 (75.9) | ||
| Others | 99/3605 (2.7) | 6/144 (4.2) | 0.311 | 3749 (75.9) | ||
| Raynaud phenomenon | 4242/4546 (93.3) | 157/165 (95.2) | 0.351 | 4711 (95.4) | ||
| Esophageal symptoms | 2721/4612 (59.0) | 99/167 (59.3) | 0.942 | 4779 (96.8) | ||
| Stomach symptoms | 1026/4536 (22.6) | 42/163 (25.8) | 0.346 | 4699 (95.1) | ||
| Intestinal symptoms | 1132/4603 (24.6) | 50/167 (29.9) | 0.116 | 4770 (96.6) | ||
| Arterial hypertension | 1040/4600 (22.6) | 50/168 (29.8) | 0.030 | 4768 (96.5) | 0.508 | |
| Scleroderma renal crisis | 59/4608 (1.3) | 21/169 (12.4) | < 0.0001 | 4777 (96.7) | 7.06 (3.77–12.2) | < 0.0001 |
| Dyspnea, significant | 481/3999 (12.0) | 18/150 (12.0) | 0.992 | 4149 (84.0) | ||
| Diffuse cutaneous subtype | 1289/4573 (28.2) | 98/169 (58.0) | < 0.0001 | 4742 (96.0) | 2.35 (1.58–3.49) | < 0.0001 |
| Scleroderma/puffy fingers | 1759/4144 (42.4) | 27/101 (26.7) | 0.739 | 4245 (85.9) | ||
| Active digital ulcers | 583/4523 (12.9) | 17/166 (10.2) | 0.316 | 4689 (94.9) | ||
| Joint synovitis | 563/4560 (12.3) | 13/167 (7.8) | 0.077 | 4727 (95.7) | ||
| Joint contractures | 1346/4489 (30.0) | 74/160 (46.3) | < 0.0001 | 4659 (94.3) | 0.104 | |
| Tendon friction rubs | 259/4479 (5.8) | 13/158 (8.2) | 0.199 | 4637 (93.9) | ||
| Muscle weakness | 802/4499 (17.8) | 30/160 (18.8) | 0.764 | 4659 (94.3) | ||
| Muscle atrophy | 417/4494 (9.3) | 18/159 (11.3) | 0.385 | 4653 (94.2) | ||
| Conduction blocks | 462/3810 (12.1) | 14/118 (11.9) | 0.932 | 3928 (79.5) | ||
| Elevated sPAP, ECHO | 628/3882 (16.2) | 18/133 (13.5) | 0.415 | 4015 (81.3) | ||
| Lung fibrosis on plain radiograph | 1046/3346 (31.3) | 42/112 (37.5) | 0.162 | 3458 (70.0) | ||
| Lung fibrosis on HRCT | 1175/2520 (46.6) | 41/74 (55.4) | 0.136 | 2594 (52.5) | ||
↵* p value after Bonferroni correction was obtained for p values < 0.007. sPAP: systolic pulmonary arterial pressure; ECHO: echocardiogram; HRCT: high-resolution computed tomography; anti-RNAP3: anti-RNA polymerase III antibodies.